T. Rowe Price Associates
BMRN icon

T. Rowe Price Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

T. Rowe Price Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.96M Buy
176,275
+18,696
+12% +$1.09M ﹤0.01% 1219
2025
Q4 		$9.37M Buy
157,579
+9,553
+6% +$520K ﹤0.01% 1247
2025
Q3 		$8.02M Buy
148,026
+10,100
+7% +$578K ﹤0.01% 1286
2025
Q2 		$7.58M Buy
137,926
+5,577
+4% +$328K ﹤0.01% 1174
2025
Q1 		$9.36M Sell
132,349
-460,044
-78% -$30.9M ﹤0.01% 1125
2024
Q4 		$38.9M Sell
592,393
-71,162
-11% -$4.77M ﹤0.01% 825
2024
Q3 		$46.6M Sell
663,555
-319,785
-33% -$26.7M 0.01% 774
2024
Q2 		$81M Sell
983,340
-118,973
-11% -$9.9M 0.01% 590
2024
Q1 		$96.3M Sell
1,102,313
-503,670
-31% -$45.1M 0.01% 559
2023
Q4 		$155M Buy
1,605,983
+401,152
+33% +$35.5M 0.02% 461
2023
Q3 		$107M Sell
1,204,831
-86,847
-7% -$7.73M 0.02% 505
2023
Q2 		$112M Sell
1,291,678
-2,369
-0.2% -$223K 0.02% 504
2023
Q1 		$126M Buy
1,294,047
+366,211
+39% +$38M 0.02% 471
2022
Q4 		$96M Buy
927,836
+316,129
+52% +$29.7M 0.02% 503
2022
Q3 		$51.9M Buy
611,707
+86,888
+17% +$7.74M 0.01% 638
2022
Q2 		$43.5M Sell
524,819
-1,064,526
-67% -$84.8M 0.01% 921
2022
Q1 		$123M Buy
1,589,345
+370,312
+30% +$31M 0.01% 665
2021
Q4 		$108M Buy
1,219,033
+4,146
+0.3% +$342K 0.01% 740
2021
Q3 		$93.9M Sell
1,214,887
-445,429
-27% -$35.1M 0.01% 790
2021
Q2 		$139M Sell
1,660,316
-250,194
-13% -$19.8M 0.01% 672
2021
Q1 		$144M Sell
1,910,510
-154,072
-7% -$12.6M 0.01% 658
2020
Q4 		$181M Buy
2,064,582
+109,300
+6% +$8.67M 0.02% 552
2020
Q3 		$149M Buy
1,955,282
+515,857
+36% +$52.2M 0.02% 551
2020
Q2 		$178M Buy
1,439,425
+25,517
+2% +$2.54M 0.02% 498
2020
Q1 		$119M Sell
1,413,908
-702,146
-33% -$60.5M 0.02% 525
2019
Q4 		$179M Sell
2,116,054
-128,267
-6% -$9.69M 0.02% 504
2019
Q3 		$151M Sell
2,244,321
-51,883
-2% -$4M 0.02% 507
2019
Q2 		$197M Sell
2,296,204
-185,337
-7% -$15.9M 0.03% 470
2019
Q1 		$220M Buy
2,481,541
+207,251
+9% +$19.2M 0.03% 441
2018
Q4 		$194M Sell
2,274,290
-158,692
-7% -$15.1M 0.03% 443
2018
Q3 		$236M Sell
2,432,982
-88,501
-4% -$8.83M 0.03% 444
2018
Q2 		$238M Buy
2,521,483
+247,675
+11% +$21.7M 0.04% 430
2018
Q1 		$184M Sell
2,273,808
-148,606
-6% -$12.8M 0.03% 481
2017
Q4 		$216M Buy
2,422,414
+413,363
+21% +$35.9M 0.04% 444
2017
Q3 		$187M Buy
2,009,051
+368,486
+22% +$32.6M 0.03% 466
2017
Q2 		$149M Buy
1,640,565
+153,834
+10% +$14M 0.03% 505
2017
Q1 		$131M Buy
1,486,731
+295,308
+25% +$26.3M 0.02% 524
2016
Q4 		$98.7M Sell
1,191,423
-1,395,706
-54% -$120M 0.02% 601
2016
Q3 		$239M Sell
2,587,129
-938,185
-27% -$88.3M 0.05% 377
2016
Q2 		$274M Sell
3,525,314
-2,693,446
-43% -$229M 0.06% 327
2016
Q1 		$513M Sell
6,218,760
-1,808,053
-23% -$147M 0.11% 213
2015
Q4 		$841M Buy
8,026,813
+491,119
+7% +$51.3M 0.18% 137
2015
Q3 		$794M Sell
7,535,694
-461,769
-6% -$61.7M 0.18% 135
2015
Q2 		$1.09B Sell
7,997,463
-177,126
-2% -$21.9M 0.23% 112
2015
Q1 		$1.02B Buy
8,174,589
+6,235,807
+322% +$661M 0.21% 117
2014
Q4 		$175M Sell
1,938,782
-98,611
-5% -$8.2M 0.04% 466
2014
Q3 		$147M Sell
2,037,393
-116,132
-5% -$7.63M 0.03% 500
2014
Q2 		$134M Sell
2,153,525
-146,424
-6% -$8.85M 0.03% 550
2014
Q1 		$157M Sell
2,299,949
-376,976
-14% -$27.8M 0.04% 496
2013
Q4 		$188M Sell
2,676,925
-167,305
-6% -$11.4M 0.04% 445
2013
Q3 		$205M Sell
2,844,230
-97,060
-3% -$6.45M 0.05% 395
2013
Q2 		$164M Buy
+2,941,290
New +$183M 0.04% 439

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's BMRN Position: Q1 2026 in Review

T. Rowe Price Associates increased its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q1 2026, buying an estimated $1.09M and bringing the position to 176,275 shares worth $9.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

T. Rowe Price Associates first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.09B in Q2 2015. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • T. Rowe Price Associates held 176,275 shares of BioMarin Pharmaceuticals worth $9.96M as of Q1 2026.
  • T. Rowe Price Associates bought 18,696 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.09M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1219 holding.
  • T. Rowe Price Associates first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's BioMarin Pharmaceuticals position peaked at $1.09B in Q2 2015.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.